The Analyst Landscape: 5 Takes On Quest Diagnostics
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Quest Diagnostics (NYSE:DGX), with ratings ranging from bullish to bearish over the last quarter. The average 12-month price target for DGX is $147.0, slightly up from the previous $146.67. Recent analyst actions include ratings and price target adjustments by Mizuho, Truist Securities, Leerink Partners, and Jefferies, reflecting varied expectations for the company's performance. Quest Diagnostics, a leading diagnostic services provider, shows a negative revenue trend with a -1.93% growth over 3 months, yet maintains strong profitability indicators such as an 8.39% net margin and above-average ROE and ROA.
April 24, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Quest Diagnostics has received varied analyst ratings, with a slight increase in the average 12-month price target to $147. Despite a negative revenue trend, the company's profitability and financial health indicators remain strong.
The mixed analyst ratings and the slight increase in the average price target suggest a neutral short-term impact on DGX's stock price. The company's strong profitability and financial health indicators, such as net margin, ROE, and ROA, support a stable outlook, counterbalancing the negative revenue trend.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100